Marstacimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hemophilia aHemophiliaSevere Hemophilia a

35 competitors in Hemophilia a

#DrugCompanyPhaseTrials

1

Hemlibra

Roche

Approved

162

Rayos

RRoxane Laboratories

Approved

13

Cyklokapron

JJ Molner

Approved

—4

Efanesoctocog Alfa

Sanofi

Phase 3

75

Advate

Takeda

Phase 3

46

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

17

Marstacimab

Pfizer

Phase 3

18

Rfviia

Roche

Phase 3

29

PF-06741086

Pfizer

Phase 3

210

SCT800

SSinocelltech Ltd.

Phase 3

4Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Severe Hemophilia a1 trial

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

Recruiting·Pfizer·Phase 1·NCT06703606·15 enrolled

Hemophilia1 trial

Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China··NCT06992076·100 enrolled

MPA1 trial

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Terminated·Pfizer·Phase 1·NCT04832139·22 enrolled

Hemophilia A or B1 trial

HYMPAVZI S.C. INJECTION 150 MG PEN SPECIAL INVESTIGATION

Active, not recruiting·Pfizer··NCT07161687·50 enrolled

Hemophilia A1 trial

AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS

Recruiting·Pfizer·Phase 3·NCT05611801·100 enrolled

Details

Drug Info

Related News